These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3323255)

  • 1. The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers.
    Carchman SH; Crowe JT; Wright GJ
    J Clin Pharmacol; 1987 Oct; 27(10):762-7. PubMed ID: 3323255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state plasma levels and pharmacokinetics of guanfacine in patients with renal insufficiency.
    Carchman SH; Sica DA; Davis J; Crowe JT; Wasserman AJ; Proctor JD; Wright GJ
    Nephron; 1989; 53(1):18-23. PubMed ID: 2674741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of guanfacine.
    Scholtysik G; Fetkovská N
    Cor Vasa; 1987; 29(4 Suppl 1):11-6. PubMed ID: 2824129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of guanfacine in patients with impaired renal function and in some elderly patients.
    Kiechel JR
    Am J Cardiol; 1986 Mar; 57(9):18E-21E. PubMed ID: 3513525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers.
    Jansat JM; Costa J; Salvà P; Fernandez FJ; Martinez-Tobed A
    J Clin Pharmacol; 2002 Dec; 42(12):1303-10. PubMed ID: 12463724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of single and multiple doses of guanfacine in essential hypertension.
    Zamboulis C; Reid JL
    Clin Pharmacol Ther; 1980 Dec; 28(6):715-21. PubMed ID: 7002428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination of guanfacine in patients with normal and impaired renal function.
    Kirch W; Köhler H; Braun W
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):33S-35S. PubMed ID: 6994776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guanfacine: a second generation alpha 2-adrenergic blocker.
    Mosqueda-Garcia R
    Am J Med Sci; 1990 Jan; 299(1):73-6. PubMed ID: 1967513
    [No Abstract]   [Full Text] [Related]  

  • 9. Concentration-dependent blood pressure effects of guanfacine.
    Frisk-Holmberg M; Wibell L
    Clin Pharmacol Ther; 1986 Feb; 39(2):169-72. PubMed ID: 2867846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and bioavailability of dilevalol in normotensive volunteers.
    Kramer WG; Nagabhushan N; Affrime MB; Perentesis GP; Symchowicz S; Patrick JE
    J Clin Pharmacol; 1988 Jul; 28(7):644-8. PubMed ID: 3216030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guanfacine kinetics in patients with hypertension.
    Weiss YA; Lavene DL; Safar ME; Simon AC; Loria Y; Georges DR; Milliez PL
    Clin Pharmacol Ther; 1979 Mar; 25(3):283-93. PubMed ID: 761440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology of centrally acting antihypertensive agents.
    Weber MA
    J Clin Pharmacol; 1989 Jul; 29(7):598-602. PubMed ID: 2668350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of guanfacine in patients undergoing haemodialysis.
    Kirch W; Kohler H; Axthelm T
    Eur J Drug Metab Pharmacokinet; 1982; 7(4):277-80. PubMed ID: 6762301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
    He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D
    Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers.
    Chang T; Black A; Dunky A; Wolf R; Sedman A; Latts J; Welling PG
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():49-56. PubMed ID: 3162901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of renal function on plasma concentration, urinary excretion and antihypertensive effect of guanfacine.
    Kirch W; Köhler H; Braun W; von Gizycki C
    Clin Pharmacokinet; 1980; 5(5):476-83. PubMed ID: 6996890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and chronic renal effects of guanfacine in essential and renal hypertension.
    Roeckel A; Heidland A
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):141S-149S. PubMed ID: 6994769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding.
    Bialer M; Wu WH; Look ZM; Silber BM; Yacobi A
    Res Commun Chem Pathol Pharmacol; 1987 Apr; 56(1):21-32. PubMed ID: 3589152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic and endocrine responses to guanfacine in normotensive volunteers and hypertensive patients.
    Rosenthal JH
    Am J Cardiol; 1986 Mar; 57(9):22E-26E. PubMed ID: 3513526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics and pharmacokinetics of pinacidil after a single dose of a new slow release tablet in healthy volunteers.
    Bareggi SR; Gambaro V; Valenti M; Benvenuti C
    Arzneimittelforschung; 1998 Jul; 48(7):730-3. PubMed ID: 9706373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.